ํ๋ฃจ๋ฉํ์
ํ๋ฃจ๋ฉํ์์ ์์ํ์์ ๊ฐ๋ ฅํ ํญ์ผ์ฆ ๋ฐ ๋ฉด์ญ ์ต์ ํน์ฑ์ ์ํด ์ฌ์ฉ๋๋ ๋งค์ฐ ๊ฐ๋ ฅํ๊ณ ์ง์ ์๊ฐ์ด ๊ธด **๋ถ์ํ ๊ธ๋ฃจ์ฝ์ฝ๋ฅดํฐ์ฝ์ด๋**์ ๋๋ค. ์ฃผ์ ์ฝ๋ฆฌํ์ ํน์ง์ ๋ค์๊ณผ ๊ฐ์ต๋๋ค: * **๋์ ์ญ๊ฐ**: ํ๋๋ก์ฝ๋ฅดํฐ์๋ณด๋ค ์ฝ 15~30๋ฐฐ ๋ ๊ฐ๋ ฅํฉ๋๋ค. * **๋ฌด๊ธฐ์ง์ฝ๋ฅดํฐ์ฝ์ด๋ ํ์ฑ ๊ฒฐ์ฌ**: ๋ฌด๊ธฐ์ง์ฝ๋ฅดํฐ์ฝ์ด๋(๋ํธ๋ฅจ ์ ๋ฅ) ํจ๊ณผ๊ฐ ๊ฑฐ์ ์์ด, ์ด์ ์ธ๋์ ์คํ ๋ก์ด๋์ ๋นํด ๋ถ์ข ๋ฐ ๊ณ ํ์์ ์ํ์ด ์ ์ต๋๋ค. * **์์์ ์ ์ฉ์ฑ**: ๊ธ์ฑ ์ผ์ฆ ๋ฐ์(์: ๊ณค์ถฉ ๋ฌผ๋ฆผ ๊ณผ๋ฏผ์ฆ, ๋ฐฑ์ ๋ฐ์, ์ผํฌ), ๊ทผ๊ณจ๊ฒฉ๊ณ ์ผ์ฆ(์ ์ก๋ญ์ผ, ๊ทผ์ก์ผ, ๊ณจ๊ด์ ์ผ) ๋ฐ ๋ค์ํ ๊ธ์ฑ ๋๋ ๋ง์ฑ ํผ๋ถ ์งํ์ ๋งค์ฐ ํจ๊ณผ์ ์ ๋๋ค. > **์์ ํต์ฌ**: ๋ชจ๋ ์ ์ ์ฑ ์ฝ๋ฅดํฐ์ฝ์คํ ๋ก์ด๋์ ๋ง์ฐฌ๊ฐ์ง๋ก ํ๋ฃจ๋ฉํ์ ์น๋ฃ์ ์ ๋ฐ์ ์ธ ๋ชฉํ๋ ์์ธ์ฑ ๋ถ์ ํผ์ง๊ธฐ๋ฅํญ์ง์ฆ(์ฟ ์ฑ ์ฆํ๊ตฐ) ๋ฐ ๋ถ์ ์ถ ์ต์ ์ ์ํ์ ์ต์ํํ๊ธฐ ์ํด *'ํ์ํ ๋งํผ๋ง, ๊ฐ๋ฅํ ์ ๊ฒ, ๊ฐ๋ฅํ ์งง์ ๊ธฐ๊ฐ ๋์'* ์ฌ์ฉํ๋ ๊ฒ์ ๋๋ค.
์์ฉ ๊ธฐ์ : Flumethasone exerts its effects via classic genomic and non-genomic steroid pathways: 1. **Genomic Pathway**: Free flumethasone crosses the cell membrane and binds to cytosolic **glucocorticoid receptors (GR)**. 2. The receptor-ligand complex translocates to the nucleus and binds to **glucocorticoid response elements (GREs)** on DNA. 3. **Transactivation**: Upregulates the expression of anti-inflammatory proteins, notably **lipocortin-1 (annexin A1)**. Lipocortin-1 inhibits **phospholipase A2** โ blocking the release of arachidonic acid from membrane phospholipids โ profoundly decreasing the synthesis of pro-inflammatory **prostaglandins** and **leukotrienes**. 4. **Transrepression**: Downregulates the expression of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha) by inhibiting transcription factors like **NF-ฮบB** and **AP-1**. 5. **Non-genomic Pathway**: Rapid physicochemical interactions with cellular membranes provide immediate effects, which is particularly beneficial in shock or acute hypersensitivity states.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Labeled indications (acute and chronic dermatoses) ยท 0.03125-0.125 mg daily in divided doses ยท PO ยท daily in divided doses ยท Tablets no longer marketed in the USA
- Labeled indications (acute and chronic dermatoses) ยท 0.03125-0.125 mg. If necessary, may repeat. ยท IV, IM, or SC ยท If necessary, may repeat
- General anti-inflammatory/immunosuppressive ยท 0.03-0.125 mg once daily ยท IV, IM, SC, or PO ยท once daily
- Labeled indications (musculoskeletal conditions, allergic states) ยท 1.25-2.5 mg daily. If necessary, the dose may be repeated. ยท IV, IM or intra-articular ยท daily ยท ARCI UCGFS Class 4 Drug
- General anti-inflammatory ยท 1-2.5 mg/450 kg ยท IV or IM
- Labeled indications (musculoskeletal conditions, dermatoses, allergic states, shock) ยท 0.0625-0.25 mg daily in divided doses ยท PO ยท daily in divided doses ยท Tablets no longer marketed in the USA
- Labeled indications ยท 0.0625-0.25 mg daily; may repeat ยท IV, IM, SC ยท daily
- Labeled indications (joint inflammation) ยท 0.166-1 mg ยท Intra-articularly
- Labeled indications (localized lesions) ยท 0.125-1 mg ยท Intra-lesionally
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Last trimester of pregnancy (may induce parturition)
- Systemic fungal infections (unless used for Addison's replacement therapy)
- Idiopathic thrombocytopenia (specifically contraindicated for IM administration)
- Known hypersensitivity to the compound
- Chronic corticosteroid therapy of systemic diseases using sustained-release injectable forms
์ด์๋ฐ์
- Polydipsia (PD), polyuria (PU), and polyphagia (PP)
- Weight gain and lipidemias
- Dull, dry haircoat and dermatological thinning
- Panting
- Gastrointestinal effects: vomiting, diarrhea, GI ulceration
- Hepatopathy: elevated liver enzymes (ALP, ALT)
- Pancreatitis
- Endocrine: activation or worsening of diabetes mellitus, iatrogenic hyperadrenocorticism (Cushingoid effects) with sustained use
- Musculoskeletal: muscle wasting, retarded growth in young animals
- Behavioral changes: depression, lethargy, viciousness
- Immunosuppression: increased susceptibility to infections
์ฝ๋ฌผ ์ํธ์์ฉ
- Amphotericin B ยท Administered concomitantly with glucocorticoids may cause hypokalemia
- Anticholinesterase agents (e.g., pyridostigmine, neostigmine) ยท In patients with myasthenia gravis, concomitant administration may lead to profound muscle weakness. Discontinue anticholinesterase at least 24 hours prior if possible.
- Aspirin ยท Glucocorticoids may reduce salicylate blood levels
- Barbiturates ยท May increase the metabolism of glucocorticoids and decrease flumethasone blood levels
- Cyclophosphamide ยท Glucocorticoids may inhibit the hepatic metabolism of cyclophosphamide; dosage adjustments may be required
- Cyclosporine ยท Concomitant administration may increase the blood levels of each by mutually inhibiting hepatic metabolism
- Diazepam ยท Flumethasone may decrease diazepam levels
- Diuretics, potassium-depleting (e.g., spironolactone, triamterene) ยท Administered concomitantly with glucocorticoids may cause hypokalemia
- Ephedrine ยท May reduce flumethasone blood levels
- Insulin ยท Insulin requirements may increase in patients receiving glucocorticoids
- Ketoconazole and other azole antifungals ยท May decrease the metabolism of glucocorticoids and increase flumethasone blood levels; ketoconazole may induce adrenal insufficiency when glucocorticoids are withdrawn
๋ชจ๋ํฐ๋ง
- Weight, appetite, and signs of edema
- Serum and/or urine electrolytes
- Total plasma proteins, albumin
- Blood glucose
- Growth and development in young animals
- ACTH stimulation test if necessary (to assess adrenal axis suppression)
๊ณผ์ฉ๋
Short-term administration of massive dosages of glucocorticoids is unlikely to cause harmful effects. There is one reported incidence of a dog developing acute CNS effects after accidental ingestion. If acute clinical signs occur, provide supportive treatment as required. Chronic overdosage or sustained high-dose usage leads to serious adverse effects, primarily manifesting as iatrogenic hyperadrenocorticism (Cushing's syndrome), characterized by severe polyuria/polydipsia, muscle wasting, alopecia, pot-bellied appearance, and immunosuppression.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.